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Cytotoxicitynd numerical decline of CD8+ Tcells during HIV infection has a profound effect on
disease progression, but only limitedmicroarray studies have used CD8+ Tcells. To understand the interactions
of HIV and host CD8+ T cells at different disease status, we used the Illumina Human-6 BeadChips to evaluate
the transcriptional proﬁle (N48,000 transcripts) in primary CD8+ T cells from HIV+ therapy-naive non-
progressors and therapy-experienced progressors. 68 differentially expressed geneswere identiﬁed, ofwhich 6
have been reported in HIV context, while others are associated with biological functions relevant to HIV
pathogenesis. By GSEA, the coordinated up-regulation of oxidative phosphorylation enzymes and interferon
responses were detected as ﬁngerprints in HIV progressors on HAART, whereas LTNP displayed a
transcriptional signature of coordinated up-regulation of components of MAPK and cytotoxicty pathways.
These results will provide biological insights into natural control of HIV versus HIV control under HAART.
Crown Copyright © 2008 Published by Elsevier Inc. All rights reserved.Introduction
HIV infects all major blood cell types and distinct HIV-1 strains
evolve independently in different blood leukocytes in vivo (Potter et al.,
2004, 2006). The interactions between HIV and different blood cell
types remain unclear and studying the subversion of human gene
machinery by HIV in different cell types may help to answer the aboveerapy; NEG, HIV sero-negative
progressor; GO, gene ontology;
very rate; OXPHOS, oxidative
e inhibitors; AZT, zidovudine;
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08 Published by Elsevier Inc. All rigquestion. Amongdifferent blood cell types, the paramount role of CD8+
T cells in HIV pathogenesis and their importance in secreting CD8
antiviral factor are well known (Mackewicz et al., 1995; Tsubota et al.,
1989; Walker et al., 1989). During acute infection, the expansion of
HIV-speciﬁc CD8+ T cells is associated with a decline in viremia (Koup
et al., 1994; Pantaleo et al., 1994). Despite their antiviral activity, CD8+
T cells can also be productively infected by HIV (Imlach et al., 2001;
McBreen et al., 2001; Saha et al., 2001). HIV-infected, therapy-naive,
long-term non-progressors (LTNP) usually maintain highly functional
CD8+ T cells, whereas HIV progressors display impaired CD8+ T cell
functions (Betts et al., 2006; Migueles et al., 2002). Although the
multiple roles of CD8+ T cells during HIV infection are well
characterized, the genetic basis of interactions between host CD8+ T
cells and HIV in relation to disease stages remain poorly understood.
Previous gene microarray studies in relation to HIV disease have
used whole PBMC or cell lines, monocytes, macrophages, CD4+ T cells,
lymphoid and gut tissue, etc (Giri et al., 2006; Ryo et al., 1999), but
only a few studies have used CD8+ T cells to understand gene
regulation during HIV infection. These include studies using CD8+ T
cell gene expression proﬁling to detect genes responsible for non-
cytotoxic activity of CD8+ T cells (Diaz et al., 2003; Martinez-Marino
et al., 2007); the study by Martinez-Marino et al. identiﬁed 52hts reserved.
Fig. 1. Clustering analysis of global gene expression proﬁles from CD8+ T cells.
Similarities in the gene expression patterns among individuals were evaluated and
visualized with BeadStudio v3 Cluster Analysis tool. The algorithm used is named
Correlation, which computes the Pearson correlation using a 1-r distance measure. The
distance on the X axis represents the similarity relationships among samples.
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CD8+ cell non-cytotoxic anti-HIV responses and uninfected controls
that lack this activity. Recently, the transcriptional proﬁling of CD4+
and CD8+ T cells from early infection, chronic infection and LTNP
patients have been studied and interferon responses were character-
ized as a transcriptional signature of T cells from early and chronic HIV
infected individuals (Hyrcza et al., 2007). It has also been shown that
CD8+ Tcells containmore differential genes than CD4+ Tcells, which is
consistent with our recent antibody microarray study illustrating that
CD8+ T cells have more cell surface molecules differentiating disease
status then CD4+ T cells (Wu et al., 2007). Despite the aforementioned
microarray studies on CD8+ T cells, a clear and comprehensive
comparison at the transcriptional level on human genome scale
between primary CD8+ T cells from therapy-naive LTNPs and HIV
progressors on HAART is lacking.
Using Illumina Human-6 v2 Expression BeadChips, we have
compared expression proﬁles of the whole human genome (N48,000
gene transcripts) in ex vivo-derived CD8+ T cells from HIV+ therapy-
naive LTNP and viremic (VIR) patients under HAART to identify
transcriptional features related to HIV disease stages and HAART
effect. The comprehensive approach of proﬁling whole human
genome in these two HIV+ patient groups has provided new insights
into virus-host interactions at the CD8+ T cell transcriptome level in
relation to disease stages and antiretroviral therapy. This will facilitate
the understanding of HIV pathogenesis and HAART effects.
Results
Cluster and differential gene analysis
CD8+ T cell-derived total cellular RNA from 9 HIV+ patients (4 LTNP
and 5 VIR, Table 1) and 5 HIV sero-negative (NEG) healthy individuals
were hybridized to the Sentrix Human-6 v2 Expression BeadChip. The
data were subjected to gene expression analysis using software
BeadStudio v3. To determine the similarity of global expression
between samples, hierarchical clustering was performed based on the
Pearson correlation metric and Correlation agglomeration method
implemented in BeadStudio. Cluster analysis revealed that the VIR
group formed an independent cluster away from LTNP and NEG
groups (Fig.1). Differential expression analysis between LTNP and NEG
showed limited differences (7 differentially expressed genes, data not
shown), which is consistent with a previous study showing lack of
differences of gene expression proﬁles between CD8+ T cells from HIV
non-progressors and negative controls (Hyrcza et al., 2007). Therefore,
our subsequent rationale was to analyze differential gene expression
in CD8+ T cells derived from VIR and LTNP groups.
Differential expression analysis between LTNP and VIR groups
revealed a candidate list of 68 genes. Each differential gene had a
detection p value b0.01 (indicating that the transcript was detected) in
at least one group, with a differential score of b−20 or N20Table 1











V1 VIR 55 334 282 2281 7.0
V2 VIR 39 2130 296 905 8.8
V3 VIR 40 4940 387 1239 8.9
V4 VIR 44 668,000 86 335 9.0
V5 VIR 61 713,000 40 70 9.3
L1 LTNP 59 b50 630 579 9.1
L2 LTNP 51 b50 714 476 8.5
L3 LTNP 79 b50 920 900 9.3
L4 LTNP 33 57 780 900 9.7
a Plasma viral load was measured using the Quantiplex HIV RNA3.0 (Chiron bDNA)
assay with a lower limit of detection of 50 HIV-1 copies/ml (Chiron Diagnostics,
Halstead, United Kingdom).corresponding to signiﬁcance level of pb0.01 (down-regulation or
up-regulation, respectively) and fold change N2.7. When compared to
the LTNP group, 57 genes were up-regulated and 11 down-regulated
in the VIR group.
For annotation of these 68 differentially expressed genes, the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) (http://david.abcc.ncifcrf.gov/) (Huangda et al., 2007) was
used as well as exhaustive searches in the PubMed literature (http://
www.ncbi.nlm.nih.gov/Literature/). These 68 genes were assigned to
eight categories according to biological functions relevant to HIV
pathogenesis as follows: (1) genes previously reported to be involved
inHIV infection anddisease (6/68); (2) Interferon induced, apoptosis and
actin-related genes (11/68); (3) cell cycle, proliferation and activation
genes (5/68); (4) adhesion and cell surface molecules (6/68); (5)
endosome, lysosome and cytotoxicity (6/68); (6) mitochondria, lipid
and carbohydratemetabolism associated genes (8/68); (7) genes lacking
relevance to HIV pathogenesis (13/68) and (8) less characterized genes
(13/68) (Table 2).
To conﬁrm the differential expression of genes from Illumina
microarray, mRNA expression levels of 18% of the randomly selected
above genes were measured by quantitative PCR (Table 3). The mRNA
from theCD8+Tcells of the samepatient at the same timepointwasused
for qPCR analysis. The fold changes evaluated by qPCR were generally
consistent with the results from microarray except for genes SLC25A20
and PYCARD, which repeatedly failed to be quantiﬁed by qPCR.
L2L analysis
To facilitate our understanding of the biological implications of
these 68 differential genes, we compared our gene list containing
these 68 differential genes to 953 differential gene lists derived from
197 published microarray data as well as 3 additional gene ontology
(GO) lists (biological process, cell component and molecule function)
using L2L microarray analysis tool (Newman and Weiner, 2005).
Detection of signiﬁcant overlap between lists may indicate the
inclusion of genes with one or more similar biological functions
deﬁned in previously published studies.
For genes up-regulated in the VIR group, several relevant themes
emerged from the L2L analysis. These include (1) interferon and TGFβ
responses and apoptotic pathways involving JAK-STAT and caspase
activation, (2) genes encoding mitochondrion components and (3)
endosome and lysomsome transport (Table 4). Although the biological
meanings derived from these lists are relevant toHIV pathogenesis and
the p values are highly signiﬁcant, the number of the actual
overlapping genes is only around 2–3 in the majority of list
comparisons, whichmay limit the derivation of the biological pathway
or mechanism involved. Thus, we attempted a complementary
approach using Gene Set Enrichment Analysis (GSEA) (Subramanian
Table 2
Differential genes grouped by the biological functions relevant to HIV pathogenesis
TargetID Gene FC Molecular function
Category I: Previously reported in HIV pathogenesis
ILMN_9420 BAG3 3.0 BCL2-associated athanogene 3 (BAG3)
ILMN_8830 ANXA2 −5.7 Annexin A2 (ANXA2), transcript variant 2, mRNA.
ILMN_21129 CHMP5 −2.8 Chromatin modifying protein 5 (CHMP5), mRNA.
ILMN_3056 PARP1 −3.0 Poly (ADP-ribose) polymerase family, member 1 (PARP1), mRNA.
ILMN_30038 RAB7 −2.9 RAB7, member RAS oncogene family (RAB7), mRNA.
ILMN_760 TRIM5 −9.6 Tripartite motif-containing 5 (TRIM5), transcript variant alpha, mRNA.
Category II: Interferon induced, cell apoptosis and actin-related genes
ILMN_1146 PYCARD −3.5 PYD and CARD domain containing (PYCARD), transcript variant 3, mRNA.
ILMN_5069 PRR5 −3.3 Proline rich protein 5 (PRR5), transcript variant 4, mRNA.
ILMN_10490 SERINC3 −3.9 Serine incorporator 3 (SERINC3), transcript variant 1, mRNA.
ILMN_6588 ACTA2 −3.8 Actin, alpha 2, smooth muscle, aorta (ACTA2), mRNA.
ILMN_13489 ARPC5 −4.3 Actin related protein 2/3 complex, subunit 5, 16 kDa (ARPC5), mRNA.
ILMN_137049 DNCL1 −4.6 Dynein, cytoplasmic, light polypeptide 1 (DNCL1), mRNA.
ILMN_18673 LY6E −3.0 Lymphocyte antigen 6 complex, locus E (LY6E), mRNA.
ILMN_35118 LOC400759 −4.7 PREDICTED: similar to Interferon-induced guanylate-binding protein 1 (GTP-binding protein 1)
(Guanine nucleotide-binding protein 1) (HuGBP-1) (LOC400759), misc RNA.
ILMN_28413 GBP1 −5.0 Guanylate binding protein 1, interferon-inducible, 67 kDa (GBP1), mRNA.
ILMN_12566 JAK2 −3.4 Janus kinase 2 (a protein tyrosine kinase) (JAK2), mRNA.
ILMN_11054 STAT1 −4.3 Signal transducer and activator of transcription 1, 91 kDa (STAT1),
transcript variant beta, mRNA.
Category III: Cell cycle, proliferation and activation related genes
ILMN_14812 JARID1B 2.8 Jumonji, AT rich interactive domain 1B (RBP2-like) (JARID1B), mRNA.
ILMN_26592 SIRPB2 −16.7 Signal-regulatory protein beta 2 (SIRPB2), transcript variant 1, mRNA.
ILMN_24322 FCRLM2 −6.0 Fc receptor-like and mucin-like 2 (FCRLM2), mRNA.
ILMN_25554 LPXN −2.7 Leupaxin (LPXN), mRNA.
ILMN_3307 BATF −3.5 Basic leucine zipper transcription factor, ATF-like (BATF), mRNA.
Category IV: Adhesion and cell surface molecules
ILMN_4953 CD9 −5.5 CD9 antigen (p24) (CD9), mRNA.
ILMN_20825 ITGA4 −4.2 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) (ITGA4), mRNA.
ILMN_23858 GPR56 −3.0 G protein-coupled receptor 56 (GPR56), transcript variant 3, mRNA.
ILMN_21540 NINJ1 3.4 Ninjurin 1 (NINJ1), mRNA.
ILMN_18826 TMEM126B −2.8 Transmembrane protein 126B (TMEM126B), mRNA.
ILMN_25105 TMEM99 −4.4 Transmembrane protein 99 (TMEM99), mRNA.
Category V: Endosome, lysosome and cytotoxicity related genes
ILMN_1682 M6PR −2.7 Mannose-6-phosphate receptor (cation dependent) (M6PR), mRNA.
ILMN_27156 HPS3 −5.5 Hermansky-Pudlak syndrome 3 (HPS3), mRNA.
ILMN_28086 GBA −4.6 Glucosidase, beta; acid (includes glucosylceramidase) (GBA), transcript variant 2, mRNA.
ILMN_3762 KLRD1 −3.1 Killer cell lectin-like receptor subfamily D, member 1 (KLRD1), transcript variant 1, mRNA.
ILMN_26813 RAC2 −2.7 Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP-binding protein Rac2) (RAC2), mRNA.
ILMN_26737 ATP6V1D −5.3 ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D (ATP6V1D), mRNA.
Category VI: Mitochondria, lipid and carbonhydrate metabolim
ILMN_16589 ACADM −6.7 Acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (ACADM), nuclear gene encoding
mitochondrial protein, mRNA.
ILMN_2603 PCK2 −3.0 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) (PCK2),
nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA.
ILMN_29792 SLC25A20 −14.3 Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20),
nuclear gene encoding mitochondrial protein, mRNA.
ILMN_4843 C10orf70 −3.5 Chromosome 10 open reading frame 70 (C10orf70), mRNA.
ILMN_13962 CAT −3.2 Catalase (CAT), mRNA.
ILMN_10698 GALM −3.1 Galactose mutarotase (aldose 1-epimerase) (GALM), mRNA.
ILMN_14503 IRS2 6.4 Insulin receptor substrate 2 (IRS2), mRNA.
ILMN_27212 THEM2 −4.1 Thioesterase superfamily member 2 (THEM2), mRNA.
Category VII: Genes lack of relevance to HIV pathogenesis
ILMN_14263 HDHD2 −3.4 Haloacid dehalogenase-like hydrolase domain containing 2 (HDHD2), mRNA.
ILMN_29250 BPNT1 −4.6 3′(2′), 5′-bisphosphate nucleotidase 1 (BPNT1), mRNA.
ILMN_19664 PREPL −5.0 Prolyl endopeptidase-like (PREPL), mRNA.
ILMN_26580 PCMT1 −4.6 Protein-l-isoaspartate (D-aspartate) O-methyltransferase (PCMT1), mRNA.
ILMN_11141 GRASP 5.8 GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein (GRASP), mRNA.
ILMN_26206 GTF2H5 −3.0 General transcription factor IIH, polypeptide 5 (GTF2H5), mRNA.
ILMN_16811 PER1 4.2 Period homolog 1 (Drosophila) (PER1), mRNA.
ILMN_12903 CRIPT −4.7 Postsynaptic protein CRIPT (CRIPT), mRNA.
ILMN_11477 ARL6IP6 −3.4 ADP-ribosylation-like factor 6 interacting protein 6 (ARL6IP6), mRNA.
ILMN_20212 OBFC2A −3.9 Oligonucleotide/oligosaccharide-binding fold containing 2A (OBFC2A), transcript variant 2, mRNA.
ILMN_20072 SULT1A4 −6.8 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 4 (SULT1A4),
transcript variant 1, mRNA.
ILMN_16255 YIPF4 −5.2 Yip1 domain family, member 4 (YIPF4), mRNA.
ILMN_17231 ZNF395 4.1 Zinc ﬁnger protein 395 (ZNF395), mRNA.
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Category VIII: Less characterized genes
ILMN_37437 BEXL1 2.6 PREDICTED: brain expressed X-linked-like 1 (BEXL1), mRNA.
ILMN_28666 C14orf142 −3.2 Chromosome 14 open reading frame 142 (C14orf142), mRNA.
ILMN_25394 CCDC53 −2.9 Coiled-coil domain containing 53 (CCDC53), mRNA.
ILMN_19806 FLJ11200 −3.4 Hypothetical protein FLJ11200 (FLJ11200), mRNA.
ILMN_16993 LOC442535 −7.0 Similar to T cell receptor gamma chain V region PT-gamma-1/2 precursor (LOC442535), mRNA.
ILMN_43020 LOC642083 −5.0 PREDICTED: hypothetical protein LOC642083 (LOC642083), mRNA.
ILMN_46540 LOC652637 6.8 PREDICTED: similar to junction-mediating and regulatory protein (LOC652637), mRNA.
ILMN_34703 LOC653743 −8.3 PREDICTED: similar to hypothetical protein DKFZp566J091 (LOC653743), mRNA.
ILMN_19396 MGC2463 −5.0 Hypothetical protein LOC79037 (MGC2463), mRNA.
ILMN_138894 SCML1 6.2 Sex comb on midleg-like 1 (Drosophila) (SCML1), mRNA.
ILMN_14718 SPCS3 −7.5 Signal peptidase complex subunit 3 homolog (S. cerevisiae) (SPCS3), mRNA.
ILMN_96342 NA −4.5 cDNA clone IMAGE:5277162
ILMN_86958 NA 5.3 cDNA FLJ41813 ﬁs, clone NT2RI2011450
FC: Fold Change, calculated by expression values of LTNP vs VIR. “−” indicates up-regulation in VIR, whereas “+” indicates up-regulation in LTNP.
Table 2 (continued)
127J.Q. Wu et al. / Virology 380 (2008) 124–135et al., 2005), which performs unbiased global search for genes that are
coordinately regulated in predeﬁned gene sets instead of examining
single differential genes.
Gene set enrichment analysis
We used the normalized data of the entire 48,000 gene transcripts
from 4 LTNP and 5 VIR samples for GSEA (Subramanian et al., 2005).
Overall, 70 gene sets were highly signiﬁcantly enriched in the VIR
group with FDRb0.01 and nominal pb0.01 (FDR cut off value,
stringentlyb0.05 and normallyb0.25). Three outstanding groups
emerged from the 70 gene sets assessed, based on the similarity of
biological meanings of the gene sets: (1) interferon responses; (2)
mitochondrion and (3) cell proliferation and differentiation (Table 5).
Within the LTNP group, only 12 gene sets were highly enriched with
FDRb0.05 and nominal pb0.01. Unlike those in the VIR group, the
biological meanings associated with these gene sets were sporadic
and their relevance to HIV disease was not obvious. However, among
the top 30 gene sets, we noticed a group of 3 gene sets (Igf1, Ngf and
insulin pathways) enriched at moderately signiﬁcant level (FDR
around 0.15 and nominal p≤0.015).
Each enriched gene set has core enrichment genes (enrichment
plot and heat map of the top core enrichment genes illustrated in
Fig. 2) and we looked for the overlap between core enrichment genes
across the gene sets possessing similar biological meanings (over-
lapping analysis illustrated in Fig. 3), as these overlapping genes may
associate with common biological processes/events. Examination of
the four enriched gene sets associated with mitochondria revealed 35
overlapping core enrichment genes with 33 encoding the oxidative
phosphorylation (OXPHOS) enzymes. 31 out of these 33 OXPHOS
enzyme genes were up-regulated uniquely in the VIR group and the
majority were up-regulated N1.2 fold (Fig. 4 illustrates the location of
these overlapping core enrichment genes in the OXPHOS pathway,
see list of genes shown in the supplementary ﬁle 1 Table 1a). This
coordinated up-regulation of the OXPHOS enzymes is a transcrip-
tional signature in viremic patients on HAART.Table 3
qPCR conﬁrmation of selected genes
Gene symbol qPCR Microarray Gene symbol qPCR Microarray
TRIM5a −4.7 −9.6 GBP1 −5.4 −5
STAT1 −9.8 −4.3 IRS2 5.8 6.4
KLRD1 −2.4 −3.1 NINJ1 3.3 3.4
CD9 −4.1 −5.5 BAG3 1.5 3
ATP6V1D −2.0 −5.3 ANXA2 −3.1 −5.7
All values represent fold change between expression levels of LTNP vs expression levels
of VIR. Minus sign indicates up-regulation in VIR whereas positive sign indicates up-
regulation in LTNP. Housekeeping gene GAPDH was used as an internal control and the
normalizer in qPCR.For Igf1, Ngf and insulin pathways enriched in LTNP, we found 9
overlapping core enrichment genes (ELK1, FOS, GRB2, MAPK3, PIK3CA,
PIK3R1, RAF1, SHC1, TYROBP) coordinately up-regulated in the LTNP
group and the majority were up-regulated N1.3 fold. Of these, GRB2,
RAF1, MAPK3, ELK1 and FOS are spread along a branch of MAPK
signaling pathway, whereas SHC, GRB2, PIK3CA, PIK3R1, RAF1 and
MAPK3 are components of NK cell-mediated cytotoxicity pathway
(Fig. 5). Notable is that this coordinated up-regulation of the
component of MAPK and cytotoxicity pathways was found to be a
transcriptional signature unique to the LTNP group.
We also did overlapping analysis for the gene sets enriched in the
VIR group related to interferon responses and cell proliferation and
differentiation. Although overlapping genes were detected, no
particular pathway was found to be enriched. Out of 9 gene sets
associated with interferon responses, 15 genes were found to be
present in at least 4 gene sets. Six of these 15 genes fell into the GO
term of virus response (STAT1, MX1, ISG15, OAS1, TRIM22 and IFI35),
and the other 9 were GBP1, OAS2, BST2, UBE2L6, TNSF10, NMI, EPS15,
IFI44L and IFIT3. For gene sets associated with cell proliferation and
differentiation, 3 out of 12 overlapping genes derived from Lee, Zhan
and Idx gene sets (Table 5) are involved in G2 phase (CCNB1, CCNB2
and CDC2; lists of genes in supplementary ﬁle 1 Table 1b). Two out of 8
overlapping genes from P21 and serum lists (Table 5) are involved in S
and G2 phase (MCM4 and BUB1; lists of genes in supplementary ﬁle 1
Table 1c). The up-regulation of the S and G2 phase genes in the VIR
group may indicate more frequent cell divisions in this group, which
is consistent with the theory of continual viral replication and rapid
CD4+ T cell turnover (Ho et al., 1995).
Discussion
In an attempt to understand the HIV and host CD8+ T cell
interactions in relation to HIV disease stages, we have evaluated the
gene expression proﬁling between CD8+ T cells from HIV+ non-
progressors and therapy-experienced progressors using the Illumina
Human-6 v2 Expression BeadChip encompassing N48,000 gene
transcripts. We detected 68 highly differential genes between the
VIR and LTNP groups. Of these, 6 have been previously reported in the
context of HIV disease (Kameoka et al., 2005; Rosati et al., 2007;
Ryzhova et al., 2006; Stremlau et al., 2004; Vidricaire and Tremblay,
2005; Ward et al., 2005), while others are known to associate with a
wide range of biological functions. Some of these functions are also
relevant to HIV disease progression, especially those involved in cell
apoptosis, proliferation, activation and cytotoxicity (Table 2). How-
ever, from the list of single differentially expressed genes, the
underlying biological mechanism could hardly be derived. Therefore
we carried out a complementary approach, the GSEA analysis, which is
able to identify signiﬁcantly differentially expressed gene sets, even
Table 4









Interferon, TGFb, Interleukin and apoptosis
Interferon
Upc L2LMDB Ifn_all_up Up-regulated 2-fold in HT1080 cells 6 h following treatment with interferon alpha, beta and gamma N10 7.2E-04
Up L2LMDB Ifn_alpha_up Up-regulated 2-fold in HT1080 cells 6 h following treatment with interferon alpha N10 2.7E-03
Up L2LMDB Ifn_any_up Up-regulated 2-fold in HT1080 cells 6 h following treatment with any of interferons alpha,
beta and gamma
N10 4.0E-04
Up L2LMDB Ifn_beta_up Up-regulated 2-fold in HT1080 cells 6 h following treatment with interferon beta N10 1.8E-04
Up L2LMDB Ifn_gamma_up Up-regulated 2-fold in HT1080 cells 6 h following treatment with interferon gamma N10 5.3E-05
Up L2LMDB ifna_hcmv_6 hrs_up Up-regulated in ﬁbroblasts at 6 h following treatment with interferon-alpha N10 4.0E-03
TGFb
Up L2LMDB tgfb_hmvec_2 h_up Up-regulated 2 h following treatment of human microvessel endothelial cells (HMVEC) with TGFbeta 6.22 1.7E-04
Up L2LMDB tgfb_hmvec_4 h_up Up-regulated 4 h following treatment of human microvessel endothelial cells (HMVEC) with TGFbeta 6.22 1.7E-04
Apoptpsis
Up GO:BP JAK-STAT cascade STAT proteins are activated by members of the JAK family of tyrosine kinases. Once activated,
STATs dimerize and translocate to the nucleus and modulate the expression of target genes.
N10 1.3E-03
Up GO:BP Apoptotic program The intracellular signaling cascade that results when a cell is triggered to undergo apoptosis N10 4.2E-03
Adipogenesis
Up L2LMDB Adip_vs_ﬁbro_dn Down-regulated following 7-day differentiation of murine 3T3-L1 ﬁbroblasts into adipocytes N10 8.6E-04
Up L2LMDB Adip_vs_preadip_dn Down-regulated in mature murine adipocytes (7 day differentiation) vs. preadipocytes
(6 h differentiation)
N10 1.5E-03
Downd L2LMDB Adip_diff_cluster2 Strongly up-regulated at 2 h during differentiation of 3T3-L1 ﬁbroblasts into adipocytes (cluster 2) N10 9.6E-03
Down L2LMDB Adipogenesis_hmsc_class2_up Up-regulated 1–14 days following the differentiation of human bone marrow mesenchymal stem cells
(hMSC) into adipocytes, versus untreated hMSC cells (Class II)
N10 3.5E-03
Endosome and lysosome
Up GO:BP Lysosome organization and
biogenesis
The formation, arrangement of constituent parts, or disassembly of lysosomes N10 7.2E-06
Up GO:BP Endosome to lysosome
transport
The directed movement of substances from endosomes to lysosomes N10 3.1E-05
Mitochondrion
Up GO:CC Mitochondrion A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the
cytoplasm of virtually all eukaryotic cells.
4.70 4.68e-03
a The database used for L2L analysis. L2LMDB represents the L2L Microarray DataBase. GO: BP, GO: CC represent lists derived from gene ontology biological process and cellular
component, respectively.
b Fold enrichment, calculated from actual matches versus expected matches in a given number of genes.
c,d: “Up” and “Down” represent up-regulation and down-regulation of expression values when VIR compared against LTNP.
128 J.Q. Wu et al. / Virology 380 (2008) 124–135where no single gene shows statistically signiﬁcant differential gene
expression between phenotypes (Mootha et al., 2003).
Using GSEA, we detected the coordinated up-regulation of
OXPHOS enzymes genes as a distinct transcriptional feature in
CD8+ T cells from the VIR group as opposed to the LTNP group.
Since all of the viremic patients had been on HAART for a con-
siderable length of time at the time of enrollment in this study, it is
plausible to hypothesize that the coordinated up-regulation of
OXPHOS enzymes could be a compensatory event to the mitochon-
drial toxicity incurred by the antiretroviral drug regimen. It is well
documented that the backbone of HAART regimens, nucleoside
reverse transcriptase inhibitors (NRTI), particularly block DNA
polymerase gamma, which is required for mtDNA synthesis
(Kakuda, 2000). In addition, impairment of mitochondrial enzymes
including adenylate kinase and the ADP/ATP translocator has also
been observed (Kakuda, 2000). All these interferences eventually
lead to mitochondrial dysfunction and depletion (Brinkman et al.,
1999; Kakuda, 2000), which underpins adverse effects of HAART
such as lactic acidosis and the lipodystrophy syndrome (Carr, 2003;
Nerurkar et al., 2003).
Our speculation that the coordinated up-regulation of OXPHOS
enzymes could be a compensatory effect of mitochondrial toxicity is
fully supported by the study of Divi et al., who documented
mitochondrial pathology during the long-term culture of human
HeLa cells in the presence and absence of zidovudine (AZT, belonging
to the drug class NRTI) for up to 77 passages (Divi et al., 2007). It
demonstrated that most OXPHOS genes were substantially up-
regulated in AZT-exposed cells at passage 5, passage 36 and passage
75 compared to unexposed cells along with other compensatoryevents such as mitochondrial proliferation and a transient increase in
mtDNA level. Similar compensatory effects have also been reported in
hepatocytes from patients receiving HAART (Kamal and French, 2004).
However, in later stages at passage 71, the signiﬁcant reduction in the
mitochondrial number, the loss of mtDNA and the abrogation of
mitochondrial function were observed, which were not manifested in
the early stages (passage 5–36) (Divi et al., 2007). This suggests that
the compensatory effects may prolong but cannot reverse the process
of mitochondrial dysfunction. This characteristic long-term adverse
effect of HAART is further conﬁrmed by a study (Aurpibul et al., 2007)
showing that in more than half of the studied population, lipodystro-
phy developed from later stages of the therapy (144 weeks), but not at
early time points (48 and 96 weeks).
Coincidently, following the submission of this manuscript, a
proteomic study has been recently reported showing that HIV
infection of the T cell line PM1 led to the up-regulation of 7 proteins
involved in OXPHOS (Ringrose et al., 2008). Interestingly, 3 out of
these 7 proteins (ATP5H, NDUFS1 and UQCRC1) were encoded by
OXPHOS genes that were found to be up-regulated in the VIR group in
our study, which implied the contribution of the viral replication to
the up-regulation of these 3 genes. Since only the minority of the 31
OXPHOS genes in our study overlapped with this proteomic study, we
further postulate that the up-regulation of the 31 OXPHOS genes could
be mostly attributed to HAART effects and only partially to the
persistent viral replication.
Both L2L and GSEA analyses revealed the interferon responses in
CD8+ Tcells fromHIV+ progressors as a transcriptional feature distinct
from LTNP, implicating the chronic immune activation status in HIV
viremic patients under HAART. Lists from the above analyses included
Table 5
Lists of the top gene sets enriched in VIR and LTNP by gene set enrichment analysis
Gene set name Gene set description NES NomP FDR
Enriched lists in VIR
Interferon responses
IFNA_HCMV_6HRS_UP Up-regulated in ﬁbroblasts at 6 h following treatment with interferon-alpha 2.21 b0.001 b0.001
DER_IFNA_UP Genes up-regulated by interferon-alpha in HT1080 (ﬁbrosarcoma) 2.12 b0.001 b0.001
SANA_IFNG_ENDOTHELIAL_UP Up-regulated by interferon-gamma in colon, derm, iliac, aortic, lung endothelial cells 2.06 b0.001 b0.001
RADAEVA_IFNA_UP Genes up-regulated by interferon-alpha in primary hepatocyte 2.04 b0.001 b0.001
DER_IFNB_UP Genes up-regulated by interferon beta in HT1080 (ﬁbrosarcoma) 1.95 b0.001 7.84E-05
IFN_ALPHA_UP Up-regulated 2-fold in HT1080 cells 6 h following treatment with interferon alpha 1.92 b0.001 1.08E-04
IFNALPHA_NL_UP Up-regulated by interferon alpha in normal primary hepatocytes 1.91 b0.001 1.54E-04
DER_IFNG_UP Genes up-regulated by interferon-gamma in HT1080 (ﬁbrosarcoma) 1.91 b0.001 1.96E-04
IFN_BETA_UP Up-regulated 2-fold in HT1080 cells 6 h following treatment with interferon beta 1.82 b0.001 2.15E-03
Mitochondria
MOOTHA_VOXPHOS Oxidative phosphorylation 1.89 b0.001 5.14E-04
HUMAN_MITODB_6_2002 Mitochondrial genes 1.85 b0.001 1.22E-03
ELECTRON_TRANSPORT_CHAIN Genes involved in electron transport 1.87 b0.001 6.64E-04
MITOCHONDRIA Mitochondrial genes 1.80 b0.001 2.89E-03
Cell proliferation and differentiation
LEE_TCELLS3_UP Transcripts enriched in both ITTP and DP more than 3 fold, with average signal value
differences of at least 100 between less mature (ITTP, DP) and more mature cells
1.95 b0.001 6.86E-05
ZHAN_MM_CD138_PR_VS_REST 50 top ranked SAM-deﬁned over-expressed genes in each subgroup_PR 1.82 b0.001 2.05E-03
IDX_TSA_UP_CLUSTER3 Strongly up-regulated at 16–24 h during differentiation of 3T3-L1ﬁbroblasts into adipocytes 1.81 b0.001 2.44E-03
P21_P53_ANY_DN Down-regulated at any timepoint (4–24 h) following ectopic expression of p21 (CDKN1A)
in OvCa cells, p53-dependent
1.79 b0.001 3.78E-03
P21_P53_MIDDLE_DN Down-regulated at intermediate timepoint (12–16 h) 1.75 0.002 7.15E-03
SERUM_FIBROBLAST_CELLCYCLE Cell-cycle dependent genes regulated following exposure to serum in a variety of human ﬁbroblast cell lines 1.75 b0.001 7.16E-03
Enriched lists in LTNP
ADIP_DIFF_CLUSTER2 Strongly up-regulated at 2 h during differentiation of 3T3-L1 ﬁbroblasts into adipocytes (cluster 2) −1.78 b0.001 2.38E-02
IGF1PATHWAY Growth factor IGF-1 stimulates growth and inhibits apoptosis by activating the MAP kinase pathway in a
variety of cell types
−1.6 0.012 1.54E-01
NGFPATHWAY Nerve growth factor (NEF) stimulates neural survival and proliferation via the TrKA and p75 receptors,
which induce DAG and IP3 production and activate Ras
−1.6 0.015 1.52E-01
INSULINPATHWAY Insulin regulates glucose levels via Ras-mediated transcriptional activation −1.58 0.011 1.54E-01
NES: normalized enrichment score; NomP: nominal p value; FDR: false discovery rate.
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supported by a previous study showing that type 1 and 2 interferon
systems are engaged as awhole to combat HIV infection from the early
to late stages (Li et al., 2004). In addition, other studies have reported
type I interferon response in HIV infection in PBMC, B and T cells
(Hyrcza et al., 2007; Moir et al., 2004). In one study, it was shown that
the interferon responses occurred early in HIV infection and may be
sustained throughout the infection in CD8+ T cells (Hyrcza et al.,
2007). Our study further extends the conclusion that interferon
responses persist in viremic patients under HAART. In contrast, the
study by Li et al. using lymph node biopsy samples showed that a large
group of interferon stimulated genes (ISGs) were down-regulated
after HAART treatment (Li et al., 2004). This discrepancy could be
explained by the following possibilities. First, only two time points,
the baseline and 1 month after therapy, were evaluated in Li's study,
while the ISG expression levels could rise over time as HAARTcan only
partially contain the chronic immune activation. Second, it is possible
that the expression level of ISG was down-regulated by HAART; it is
still higher than those detected in LTNP. Besides the interferon
responses, the signiﬁcantly up-regulated genes associated with cell
apoptosis, such as PYCARD and those overlapping with the TGF-β
stimulated gene lists also illustrated the chronic immune activation
status in the VIR group.
The 15 overlapping core enrichment genes associated with
interferon responses not only included well characterized genes
such as STAT1, OAS1 and OAS2, MX and GBP1 involved in IFN
signaling, RNA degradation and virus replication inhibition (Samuel,
2001), but also encompassed the very recently characterized TRIM 22
and BST genes. TRIM22 overexpression has been reported to inhibit
HIV replication, and in TRIM22 depleted cells HIV particle release was
signiﬁcantly increased (Barr et al., 2008). BST2, a membrane protein
of previously unknown function, was characterized as a tetherin,
which can inhibit HIV release through retention of virions on cellsurfaces (Neil et al., 2008). More than half of the 15 genes are less
characterized such as TNSF10 associated with induction of CD4+ T
cell death (Herbeuval et al., 2005), NMI and IFI35 involved in
cytokine signaling (Zhang et al., 2007), and EPS15 involved in
clathrin-dependent endocytosis (Daecke et al., 2005). As the common
presence of these genes in a number of interferon response lists may
indicate some common biological roles, further investigation of the
less characterized genes and the biological synergy between them is
warranted.
GSEA also revealed the coordinated up-regulation of the compo-
nents of the MAPK and NK cell-mediated cytotoxicity pathways as a
distinct transcriptional feature unique to the LTNP group when
compared to the VIR group. This is possibly related to CD8+ T cell-
mediated cytotoxicity function. The multiple roles of the MAPK
signaling pathway, such as activating HIV-1 replication and involve-
ment in endothelial cell proliferation, have been reported in HIV
disease (Toschi et al., 2006; Yang et al., 1999). Despite these roles, this
pathway has also been documented in relation to NK effector function,
which is associated with the mobilization of granule components
(Berg et al., 1998; Wei et al., 1998).
Interestingly, part of the up-regulated components of MAPK
pathway (GRB2, RAF1 and MAPK3), together with other three core
enriched genes (SHC, PIK3CA and PIK3R1) are distributed along two
branches of NK cell-mediated ctytoxicity pathway (Fig. 5); one is
signaling through SHC, GRB2, and RAF, and the other through PI3K,
with both branches converge at MEK1/2 signaling to ERK1/2 (MAPK).
The biological processes involved in this NK cytotoxicity pathway are
also common to other cytotoxic cells including cytotoxic T lympho-
cyte (CTL), NK T cells and γδ T cells (Russell and Ley, 2002). As MAPK
pathway also has implications in cytotoxicity function as discussed
above, we thus hypothesize that the up-regulated components of
these two pathways in LTNP are possibly associated with the effective
cytoxicity function in this group, which is consistent with strong anti-
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drug-free survival. Interestingly, the differential analysis detected the
signiﬁcant up-regulation of the inhibitory NK cell receptor CD94 in
the VIR group. CD94, also expressed on activated CD8+ T cells,
functions together with NKG2 to inhibit cell-mediated cytotoxicity
(Moser et al., 2002; Zeddou et al., 2007). The up-regulation of this
molecule may suggest impaired CTL in the VIR group as opposed to
the LTNP group.
L2L analysis also picked up a few genes associated with endosome
and lysosome transport signiﬁcantly up-regulated in the VIR group
(M6PR, CHMP5 and GBA), which may be related to HIV entry via
clathrin-mediated endocytosis and budding at late endosomes
(Daecke et al., 2005; Damme and Guatelli, 2008; Ward et al., 2005).
Both L2L and GSEA analysis have signiﬁcantly overlapping gene lists
associated with adipocyte differentiation, but the biological relevance
of this gene regulation remains to be elucidated.
The most notable feature of this study is that it distinguishes
genetic regulation of CD8+ T cell transcriptome between HIV+ viremic
patients on HAARTand therapy-naive LTNPs. In summary, coordinated
up-regulation of oxidative phosphorylation enzymes and interferon
responses in the VIR group and coordinated up-regulation of
components of MAPK and cytotoxicity pathways in the LTNP group
are the transcriptional signatures that characterize these two groups.
The up-regulation of 31 OXPHOS genes in the VIR group could be
mostly attributed to HAART effects and only partially to persistent
viral replication. Though mitochondrial toxicity incurred by HAART
has been recognized for some years, this study is ﬁrst to show the
compensatory effect of mitochondrial toxicity at the genetic level in ex
vivo collected CD8+ T cells from HIV+ progressors, indicating the
oxidative stress induced by HAART during HIV disease progression.
Further characterization of these genes may facilitate a clear under-
standing of HAART-induced oxidative stress toxicity and various
metabolic disturbances down to the individual gene level. This may
also aid the development of new therapeutic modalities. The persisted
interferon responses in viremic patients on HAART suggested the
chronic immune activation status in these patients. The coordinated
up-regulation of components of MAPK and cytotoxicity pathways in
the LTNP group leads to the hypothesis that this may be one of the
molecularmechanisms contributing to the effective and sustained CTL
activity in the LTNPs, which may also be one of the major protective
correlates during asymptomatic HIV disease. Overall, these results
offer new comparative insights into HIV and host cell interactions in
relation to HAART treatment and disease status. This will further
facilitate the understanding of the genetic basis of progressive and
non-progressive HIV disease as well as gene regulation during HAART
in primary CD8+ T cells. A deeper understanding of interactions
between HIV and individual cell types is sorely needed, if new
therapeutic interventions have to be designed or information on
innate /adaptive genes governing the natural control of HIV in LTNPs
have to be identiﬁed and characterized.
Materials and methods
Patient proﬁles
Four HIV infected long-term non-progressors (LTNP; n=4) and ﬁve
HIV+ patients on HAART with detectable plasma viremia (VIR; n=5)Fig. 2. Enrichment plot and heat map for the gene sets of electron transport chain and inter
transport chain. Bottom, plot of the ranked list of all genes. Yaxis, value of the rankingmetric
with the VIR or LTNP group get the highest metric scores with positive or negative sign, and a
set electron transport chainwithin the ranked list. Top, the running enrichment score for the g
enrichment score (ES) for this gene set and those genes appear before or at the peak are deﬁne
genes from the gene set of electron transport chain. The genes that contributemost to the ES,
core enrichment genes. Rows, gene; columns, samples. Range of colors (red to blue) show
SANA_IFNG_Endothelial_Up. (D) Heat map of the top 32 core enrichment genes from the gewere studied. The infection time for L1, L2 and L3 are N20 years,
and L4 N14 years. These treatment-naive LTNPs have maintained
high CD4+ T cell counts (N500 cells/μl) and below detectable levels
of plasma viremia (b50 copies of HIV RNA/ml plasma) except one
patient (L4) with very low plasma viremia (57 HIV RNA copies/ml
plasma) (Table 1). In contrast, patients in the VIR group were on
HAART and had detectable plasma viremia and CD4+ T cell counts
b500 cells/μl. These patients received two NRTIs in association with
one or two protease inhibitors except V3 who received combined
therapy of one NNRTI (etravirine), two protease inhibitors and one
integrase inhibitor (raltegravir). The NRTIs the patients received
included zidovudine, lamivudine, stavudine, emtricitabine and teno-
fovir; the protease inhibitors included darunavir, ritonavir, indinavir,
saquinavir, and atazanavir. Five HIV sero-negative and otherwise
healthy individuals were included as controls to compare gene
expression proﬁles and validate our system. Six patients came from
the HIV clinic at Westmead Hospital and three patients plus the ﬁve
healthy controls came from the Australian Red Cross Blood Service in
Sydney. This study was approved by the Sydney West Area Health
Services Research Ethics Committee (HREC2008/2/4.12(2732)), and all
blood samples were collected after individual informed consent.
Puriﬁcation of CD8+ T cells and RNA isolation
A single blood sample (10 ml in EDTA) was obtained from each
patient. After separation of plasma, PBMC were isolated immediately
after obtaining blood samples by Ficoll-gradient centrifugation and
puriﬁed. This aspect was strictly followed because of previously
described lower RNA yields and possible changes in gene expression
proﬁles upon storage of blood (Lyons et al., 2007). CD8+ T cells were
then obtained by positive isolation with antibody-conjugated
magnetic beads according to the manufacturer's instructions
(Dynal Biotech, Oslo, Norway). Lyons et al., have also shown that
it is preferable to use positive selection to avoid contaminating cells
in puriﬁed fractions (Lyons et al., 2007). Flow-cytometric analysis
performed on separated CD8+ T cell populations demonstrated that
99.1%±0.128 (mean ±SD) of puriﬁed CD8+ cells were single positive
for the CD8 marker (Potter et al., 2004). Total RNA was isolated from
puriﬁed cells using RNeasy Mini kit (Qiagen Pty Ltd., Clifton Hill,
Victoria, Australia) with an integrated step of on-column DNase
treatment.
cRNA preparation, microarray hybridization and scanning
RNA quality was checked by Agilent Bioanalyzer and RNA Integrity
Scores are shown in Table 1. cRNA ampliﬁcation and labeling with
biotin were performed using Illumina TotalPrep RNA ampliﬁcation kit
(Ambion, Inc., Austin, USA) with 250 ng total RNA as input material.
cRNA yields were quantiﬁed with Agilent Bioanalyzer and 1.5 μg
cRNAs were hybridized to the Sentrix Human-6 v2 Expression
BeadChips (Illumina, Inc., San Diego, USA). Each chip contains six
arrays and each array contains N48,000 gene transcripts, of which,
46,000 derived from human genes in the National Center for
Biotechnology Information (NCBI) Reference Sequence (RefSeq) and
UniGene databases. All reagents and equipment used for hybridiza-
tion were purchased from Illumina, Inc. According to the manufac-
turer's protocol, cRNAwas hybridized to arrays for 16 h at 58 °C beforeferon-gamma induced genes by GSEA. (A) Enrichment plot for the gene set of electron
; X axis, the rank for all genes. Genes whose expression levels are most closely associated
re located at the left or right edge of the list. Middle, the location of genes from the gene
ene set as the analysis walks along the ranked list. The score at the peak of the plot is the
d as core enrichment genes for this gene set. (B) Heat map of the top 38 core enrichment
i.e., genes that appear in the ranked list before or at the peak point of ES, were deﬁned as
s the range of expression values (high to low). (C) Enrichment plot for the gene set of
ne set of SANA_IFNG_Endothelial_Up.
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Fig. 3. Core enrichment genes overlap in the four gene sets associated with mitochondrion. Rows, gene set; columns, genes. The core enrichment gene in each gene set was
represented by a colored cell. Range of colors (red to blue) shows the range of enrichment signal (high to low). Common core enrichment genes across gene sets formed vertical
stripes.
Fig. 4. Coordinately up-regulated OXPHOS genes in the VIR group illustrated in oxidative phosphorylation pathway obtained from Kyoto Encyclopedia of Genes and Genomes (KEGG;
http://www.genome.jp/kegg/). Top, 3D illustrations of the electron transport chain. Enzyme identiﬁers (e.g. 1.6.5.3, 1.6.99.3, etc; according to KEGG namespace) associated with up-
regulated genes are highlighted in red. Bottom, the subunit components of the 5 enzyme complexes along the electron transport chain. The proteins encoded by the 31 coordinately
up-regulated genes are highlighted in red and these include (1) Complex I NADH dehydrogenase subunits (NDUF) S1, S4, S6, A3, A7, A8, AB1, B2, B3, B5, B6, B7 and C1, (2) Complex II
succinate dehydrogenase subunits (SDH) C and D, (3) Complex III cytochrome c reductase components COR1, QCR2, QCR6 and QCR7, which are encoded by (UQCR) C1, C2, H, and B,
respectively, (4) Complex IV cytochrome c oxidase subunits (COX) 5A, 6A1, 7B, 11, and 15, and (5) Complex V ATP synthase units gamma, delta, epsilon, b, d, f6 and f encoded by ATP
5C1, 5D, 5E, 5F1, 5H, 5J and 5J2, respectively.
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Fig. 5. Coordinately up-regulated components of MAPK and cytotoxicity pathways in the LTNP group illustrated in the pathways obtained from Kyoto Encyclopedia of Genes and
Genomes (KEGG; http://www.genome.jp/kegg/). Top, the classical MAPK pathway adopted from MAPK pathway. The proteins GRB2, RAF1, ERK (corresponding to gene symbol
MAPK3), ELK-1 and C-FOS (corresponding to gene symbol FOS) encoded by the coordinately up-regulated genes are highlighted in red and denoted by dots. Bottom, NK cell-mediated
cytotoxicity pathway. The proteins SHC (corresponding to gene symbol SHC1), GRB2, RAF (corresponding to gene symbol RAF1), PI3K (corresponding to gene symbol PIK3CA and
PIK3R1) and ERK1/2 (corresponding to gene symbol MAPK3) encoded by coordinately up-regulated genes are highlighted in red and denoted by dots.
133J.Q. Wu et al. / Virology 380 (2008) 124–135being washed and stained with streptavidin-Cy3. Then the beadchips
were centrifuged to dry and scanned on the Illumina BeadArray
Reader confocal scanner.
Differential gene and L2L analysis
BeadStudio version 3 was used to analyze Illumina data. Hybridi-
zation controls showed that inter-array variability was within a levelappropriate for normalization. Signal levels were good and noise and
background levels were low. Following normalization of all samples
using a cubic spline function (www.illumina.com/downloads/
GXBeadStudioNormalization_TechNote.pdf) (see supplementary ﬁle
2 Table 2), cluster analysis for the whole genome expression of 48,000
human gene transcripts was performed based on the Pearson
correlation metric and Correlation agglomeration method implemen-
ted in BeadStudio.
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groups, the differential analysis was carried out for 4 LTNP and 5 VIR
samples using a cubic spline function for normalization and the
Illumina custom error model with false discovery rate correction
implemented in BeadStudio (Benjamini and Hochberg, 1995). Genes
with detection pb0.01 (indicating the transcript was detected) in at
least one group were selected. With at least one group has detected
transcripts, differential genes were identiﬁed by DiffScore N20 or
b−20 (corresponding to signiﬁcance level of Pb0.01). DiffScore, the
expression difference score, takes into account background noise and
sample variability (Chudin et al., 2006). The list of differential genes
was then submitted through L2L analysis tool (http://depts.washing-
ton.edu/l2l/) to compare with 953 differential gene lists from L2L
microarray database.
Gene set enrichment analysis
Gene set enrichment analysis of the normalized data comprising
the entire 48,000 transcripts from 4 LTNP and 5 VIR was performed
using the GSEA software (Subramanian et al., 2005) version 2.0
obtained from Broad Institute (http://www.broad.mit.edu/gsea). First,
a ranked list was obtained by ranking all genes according to the
correlation between their expression and the group distinction using
the metric signal to noise ratio. Then the association between a given
gene set and the group distinction was measured by the non-
parametric running sum statistic termed the enrichment score (ES),
which was calculated by walking down the ranked list, increasing
when encountering a gene in the given gene set and decreasing when
encountering a gene not in the gene set (Fig. 2A). To estimate the
statistical signiﬁcance of the ES, a nominal p value was calculated by
permuting the genes 1,000 times. To adjust for multiple hypothesis
testing, the maximum ES was normalized to account for the gene set
size (NES) and the false discovery rate (FDR) corresponding to each
NES was calculated. The gene sets used is from Molecular Signatures
Database (MsigDB) (Subramanian et al., 2005), catalog C2 functional
sets, which include 639 gene sets from pathway databases and 1186
gene sets that represent gene expression signatures of genetic and
chemical perturbations (as updated by April, 2008). The overlapping
core enrichment genes between gene sets were examined by the
leading edge analysis tool implemented in GSEA software. To identify
KEGG pathways that these overlapping core enrichment genes are
involved, WebGestalt (Web-based Gene SeT AnaLysis Toolkit) was
used (Zhang et al., 2005).
Real time quantitative PCR
Puriﬁed total cellular RNAwas reverse transcribed using oligo d(T)
and Superscript III followed by RNase H treatment (Invitrogen Life
Technologies). The cDNA was then subject to real time quantitative
PCR with deﬁned primers and SYBR Green (Invitrogen Life Technol-
ogies) using Mx3005P™ QPCR System (Stratagene). The relative
quantitation method was used to evaluate the expression of selected
genes with the housekeeping gene GAPDH as an internal control and
the normalizer for all data. Primer sequences for each transcript are
available from the authors on request.
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